PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28177277-0	2017	Prevalence of bisphosphonate therapy in women with breast cancer treated with aromatase inhibitors in Germany : .	Diphosphonates	14-28	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	78-87	
28177277-1	2017	PURPOSE: The aim of this study is to analyze the prevalence of bisphosphonate therapy in women with breast cancer (BC) treated with aromatase inhibitors (AI) in Germany.	Diphosphonates	63-77	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	132-141	
24367197-0	2012	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.	Diphosphonates	65-80	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	0-9	
17845332-0	2007	Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.	Diphosphonates	68-82	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	0-9	
17845332-1	2007	AIM: To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.	Diphosphonates	88-102	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	20-29	
35456610-7	2022	Several SNPs located in genes FDPS and FNTA were associated with the bisphosphonate-induced changes in hip bone mineral density (BMD), whereas polymorphisms of the PDSS1, CYP19A1, CYP1A1, and CYP1A2 genes were associated with SERM-induced changes in spine BMD.	Diphosphonates	69-83	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	171-178